Clementia Pharmaceuticals Inc.
CMTA
CMTA was delisted on the 17th of April, 2019.
27 hedge funds and large institutions have $263M invested in Clementia Pharmaceuticals Inc. in 2018 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 5 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
7% less funds holding
Funds holding: 29 → 27 (-2)
13% less capital invested
Capital invested by funds: $301M → $263M (-$37.9M)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$7.8M |
| 2 |
AG
Artal Group
Luxembourg
|
+$5.18M |
| 3 |
JP Morgan Chase
New York
|
+$1.63M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$1.57M |
| 5 |
BC
Birchview Capital
Burlington,
Vermont
|
+$568K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.58M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.97M |
| 3 |
LCM
Laurion Capital Management
New York
|
-$1.2M |
| 4 |
D.E. Shaw & Co
New York
|
-$211K |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$159K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
26
Tower Research Capital (TRC)
New York
| $5K | -$14.3K | -1,357 | -75% |
|
|
27
Fidelity Investments
Boston,
Massachusetts
| – | -$6.58M | -500,000 | Closed |
|
|
28
Alyeska Investment Group
Chicago,
Illinois
| – | -$2.97M | -225,862 | Closed |
|
|
29
D.E. Shaw & Co
New York
| – | -$211K | -16,026 | Closed |
|
|
WJA
30
Williams Jones & Associates
New York
| – | -$133K | -10,100 | Closed |
|
|
AAMU
31
Amundi Asset Management US
Boston,
Massachusetts
| – | -$61K | -4,600 | Closed |
|
CMTA Hedge Fund Activity: Q3 2018 in Review
27 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Clementia Pharmaceuticals Inc. (CMTA) for Q3 2018, worth a combined $263M — down 13% from $301M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CMTA and 3 opened new positions — a net loss of 2 holders — while 8 trimmed existing stakes and 8 added.
The largest buyer was Baker Bros. Advisors, adding an estimated $7.8M. The largest seller was Fidelity Investments, exiting entirely with an estimated $6.58M sold.
- 27 institutional investors held Clementia Pharmaceuticals Inc. (CMTA) as of Q3 2018, down from 29 in Q2 2018.
- Funds reported $263M of Clementia Pharmaceuticals Inc. stock for Q3 2018, down 13% quarter-over-quarter.
- 3 funds opened new Clementia Pharmaceuticals Inc. positions in Q3 2018 and 5 closed out, a net change of -2 holders.
- The largest Clementia Pharmaceuticals Inc. buyer in Q3 2018 was Baker Bros. Advisors, an estimated $7.8M added.
- The largest Clementia Pharmaceuticals Inc. seller in Q3 2018 was Fidelity Investments, an estimated $6.58M sold.
Based on aggregated 13F filings for Q3 2018.